BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia

Leukemia

Volumn 27, Issue 1, 2013, Pages 251-252

  Buitenkamp, T D ^a   Pieters, R ^a,b   Zimmermann, M ^c   De Haas, V ^b   Richards, S M ^d   Vora, A J ^e   Mitchell, C D ^f   Schwab, C ^g   Harrison, C J ^g   Moorman, A V ^g   Van Den Heuvel Eibrink, M M ^a   Zwaan, C M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL TRANSLOCATION GENE 1; CHILD; COHORT ANALYSIS; DOWN SYNDROME; EVENT FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; TRISOMY 21;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA, NEOPLASM; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; INFANT; MALE; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873568668     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.199     Document Type: Letter

References (15)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169.
2. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005; 106: 4043-4049.
3. Buitenkamp T, Forestier E, Heerema NA, van den Heuvel MM, Pieters R, de Haas V et al. Acute Lymphoblastic Leukemia in children with Down Syndrome: a report from the Ponti di Legno Study group. ASH: San Diego, 2011.
4. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008; 111: 1575-1583.
5. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006-1017.
6. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al. Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-1246.
7. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
8. Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB et al. Outcome in children with Down syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012; e-pub ahead of print 22 March 2012; doi:10.1038/leu.2012.84.
9. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007; 21: 1258-1266.
10. Tsuzuki S, Karnan S, Horibe K, Matsumoto K, Kato K, Inukai T et al. Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization. Cancer Sci 2007; 98: 698-706.
11. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L et al. BTG1, a member of a new family of antiproliferative genes. Embo J 1992; 11: 1663-1670.
12. Rimokh R, Rouault JP, Wahbi K, Gadoux M, Lafage M, Archimbaud E et al. A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 1991; 3: 24-36.
13. Rouault JP, Samarut C, Duret L, Tessa C, Samarut J, Magaud JP. Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3' non-coding regions. Gene 1993; 129: 303-306.
14. Lundin C, Hjorth L, Behrendtz M, Nordgren A, Palmqvist L, Andersen MK et al. High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome. Genes Chromosomes Cancer 2012; 51: 196-206.
15. van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B et al. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood 2010; 115: 4810-4819.